Malaria in the 21st century - still a threatening problem

There are six parasite species (P. falciparum, P. vivax, P. ovale curtisi, P. ovale wallikeri, P. malariae, and P. knowlesi) that cause malaria in humans. P. falciparum is responsible for most malaria-related deaths globally. P. vivax is the dominant malaria parasite in most countries outside of the Sub-Saharan Africa. In 2016, 91 countries reported a total of 216 million cases of malaria. The global tally of malaria deaths reached 445,000. In 2016, 24 cases of imported malaria were registered in the Republic of Serbia, with an incidence of 0.33/100,000. According to the World Health Organization recommendations, every suspected malaria case should be confirmed by microscopy or a rapid diagnostic test before treatment. The main stone of antimalarial therapy should be artemisinin-based combinations. Since malaria occurs in Europe as an imported (though rarely also autochthonous and a hospital-borne infection), the objective of this paper is to point out current problems and attitudes in the diagnosis and treatment of malaria, without entering the data field significant for professionals (infectologists, epidemiologists, intensivists).

[1]  N. Becker,et al.  Distribution of Anopheles daciae and other Anopheles maculipennis complex species in Serbia , 2018, Parasitology Research.

[2]  J. Rayner,et al.  Malaria Vaccines: Recent Advances and New Horizons , 2018, Cell host & microbe.

[3]  E. Ashley,et al.  Drugs in Development for Malaria , 2018, Drugs.

[4]  N. White,et al.  Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria , 2018, PLoS neglected tropical diseases.

[5]  Hospital-acquired malaria infections in the European Union 30 April 2018 , 2018 .

[6]  T. Shamsi,et al.  Laboratory Diagnosis of Malaria: Comparison of Manual and Automated Diagnostic Tests , 2017, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[7]  T. Rolling,et al.  Severe malaria in Europe: an 8-year multi-centre observational study , 2017, Malaria Journal.

[8]  G. Daikos,et al.  Malaria in Europe: emerging threat or minor nuisance? , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  Bhimanna Kuppast,et al.  4-aminoquinolines: An Overview of Antimalarial Chemotherapy , 2016 .

[10]  S. Iyer,et al.  Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study , 2015, Malaria Journal.

[11]  M. Eyasu Antimalarial Drug Resistance: In the Past, Current Status and Future Perspectives , 2015 .

[12]  M. Pavlović,et al.  Clinical significance of molecular methods in the diagnosis of imported malaria in returning travelers in Serbia. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  P. Schlagenhauf,et al.  Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. , 2014, Travel medicine and infectious disease.

[14]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[15]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[16]  J. Kevin Baird Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life — averting the infectious bite preempts these hazards , 2013, Pathogens and global health.

[17]  A. Kaiser,et al.  Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study , 2012, Malaria Journal.

[18]  Michael L Wilson Malaria rapid diagnostic tests. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Mary H H Ensom,et al.  Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria , 2012, The Annals of pharmacotherapy.

[20]  K. Vaidya,et al.  QUANTITATIVE BUFFY COAT (QBC) TEST AND OTHER DIAGNOSTIC TECHNIQUES FOR DIAGNOSIG MALARIA: REVIEW OF LITRATURE - , 2012 .

[21]  B. Milošević,et al.  Imported malaria in Belgrade, Serbia, between 2001 and 2009 , 2011, Wiener klinische Wochenschrift.

[22]  P. B. Mindolli,et al.  Comparative Study of Peripheral Blood Smear, QBC and Antigen Detection in Malaria Diagnosis , 2011 .

[23]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[24]  X. Su,et al.  Discovery, mechanisms of action and combination therapy of artemisinin , 2009, Expert review of anti-infective therapy.

[25]  M. Eisenhut,et al.  Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review , 2008, Malaria Journal.

[26]  M. Pavlović,et al.  ECOLOGY OF ANOPHELES MOSQUITOES IN BELGRADE AREA. ESTIMATING VECTOR POTENTIAL FOR MALARIA RETRANSMISSION , 2008 .

[27]  David G Lalloo,et al.  UK malaria treatment guidelines. , 2007, The Journal of infection.

[28]  A. W. Woodruff,et al.  The Prophylaxis of Malaria , 1916, The Lancet.